Annukka Marjamaa

Conflicts of Interest Markus Sane consultancy fees (Abbott, Biotronik, Medtronic), travel grants (Biotronik). Jarkko Karvonen speaker honoraria and/or consultancy fees (Medtronic, Biotronik, Abbott and Boston Scientific), advisory board (Medtronic). Pekka Raatikainen speaker honoraria/consultancy fees (Biosense Webster, Stereotaxis). The remaining authors have nothing to disclose.

Implantable cardioverter-defibrillator (ICD) therapy is generally considered the first-line treatment for patients with aborted sudden cardiac death (SCD) or elevated risk of life-threatening ventricular arrhythmias [1]. The incidence and risk factors for appropriate and inappropriate therapies have been well described in the literature [2]. However, less attention has been paid to modifiable predisposing factors such as cessation of antiarrhythmic medication and excessive alcohol consumption.